^
Association details:
| Biomarker: | RET M918T |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Excerpt:
Of the two patients with PR, one had hereditary MTC with the RET C634R mutation, and the other had sporadic MTC with the RET M918T mutation.
DOI:
10.1200/JCO.2009.25.0068
Trial ID:
